EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma

Naseem Esteghamat, Aaron Tsumura, Gabriel Marquez-Arreguin, Joseph Tuscano

Frontiers in Oncology · 22.10.2024 · 14

DOI: 10.3389/fonc.2024.1481950 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 22.10.2024. Verfasst von Naseem Esteghamat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis Comprehensive Cancer Center, Sacramento, CA, U…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the curative-intent treatment for patients who demonstrated chemosensitivity to salvage therapy. However, a significant portion of patients do not make it autoHCT due to disease progression or overall fitness and eligibility. This is of particular concern in the older adult population. In recent years, significant advances in cellular therapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, in addition to improvement in autoHCT tolerability, have allowed for additional treatment options for patients with R/R DLBCL. These novel therapies offer the potential for durable remissions and cure, and should be considered in older patients. We present a review focused on the safety and efficacy of cellular therapies in the older adult population with R/R DLBCL.

Schlagwörter

Stichwörter der Autor:innen

CAR TCAR T cellDLBCL - diffuse large B cell lymphomaautologous transplant (ASCT)bispecific antibody (bsAb)elderly

Autor:innen und Institutionen

  • Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.
  • Division of Hematology & Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States.
  • Schoool of Medicine, University of California, Davis, Sacramento, CA, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Esteghamat, N., Tsumura, A., Marquez-Arreguin, G., & Tuscano, J. (2024). Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1481950

Vancouver

Esteghamat N, Tsumura A, Marquez-Arreguin G, Tuscano J. Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1481950

BibTeX
@article{Esteghamat2024,
  author = {Esteghamat, Naseem and Tsumura, Aaron and Marquez-Arreguin, Gabriel and Tuscano, Joseph},
  title = {Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1481950}
}
Kostenlos starten →